Eli Lilly and Company (LLY) Key Metrics
LLY valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.12T
- Enterprise value
- $1.07T
- P/E (TTM)
- 42.2 10-yr median 46.8
- Forward P/E
- 24.4
- PEG ratio
- 1.14
- Price / sales
- 14.1 10-yr median 7.9
- Price / book
- 30.3 10-yr median 31.0
- EV / EBITDA
- 25.7 10-yr median 27.3
- Dividend yield
- 0.55% $6.92 a year
- Beta
- 0.45
LLY key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsLLY valuation Price multiples at each fiscal year-end price.
LLY returns How much profit the business earns on the capital it uses.
LLY per-share figures Results divided by the shares outstanding at year-end.
LLY financial health Debt, liquidity and how easily interest is covered.
LLY efficiency & capital use Working capital cycle and where the cash goes.
LLY valuation history
LLY returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LLY debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LLY cash returned to shareholders
LLY price vs earnings per share
LLY key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $965.06B | $697.93B | $526.54B | $347.61B | $263.42B | $161.51B | $125.85B | $119.62B | $88.85B | $80.97B |
| Enterprise value | $1.00T | $728.15B | $548.84B | $361.64B | $276.39B | $174.42B | $139.21B | $124.95B | $94.47B | $85.24B |
| P/E ratio | 46.8 | 65.9 | 100.5 | 55.7 | 47.2 | 26.1 | 15.1 | 37.0 | — | 29.6 |
| Price / sales | 14.8 | 15.5 | 15.4 | 12.2 | 9.3 | 6.6 | 5.6 | 5.6 | 4.4 | 3.8 |
| Price / book | 36.4 | 49.2 | 48.9 | 32.6 | 29.3 | 28.6 | 48.3 | 11.0 | 7.7 | 5.8 |
| Price / free cash flow | 107.6 | 185.6 | — | 75.6 | 48.9 | 36.1 | 36.1 | 47.7 | 25.7 | 21.5 |
| Price / operating cash flow | 57.4 | 79.1 | 124.2 | 49.1 | 36.3 | 24.8 | 26.0 | 21.7 | 15.8 | 16.7 |
| EV / sales | 15.3 | 16.2 | 16.1 | 12.7 | 9.8 | 7.1 | 6.2 | 5.8 | 4.7 | 4.0 |
| EV / EBITDA | 31.6 | 38.7 | 64.1 | 41.8 | 34.4 | 19.6 | 20.2 | 22.6 | 23.1 | 16.9 |
| EV / free cash flow | 111.5 | 193.7 | — | 78.6 | 51.3 | 39.0 | 40.0 | 49.9 | 27.4 | 22.7 |
| Earnings yield | 2.1% | 1.5% | 1.0% | 1.8% | 2.1% | 3.8% | 6.6% | 2.7% | −0.2% | 3.4% |
| Free cash flow yield | 0.9% | 0.5% | −0.6% | 1.3% | 2.0% | 2.8% | 2.8% | 2.1% | 3.9% | 4.6% |
| Dividend yield | 0.6% | 0.7% | 0.8% | 1.0% | 1.2% | 1.7% | 1.9% | 1.9% | 2.5% | 2.7% |
| Shareholder yield (dividends + buybacks) | 1.0% | 1.0% | 0.9% | 1.4% | 1.6% | 2.0% | 5.4% | 5.4% | 2.8% | 3.4% |
| Share price at fiscal year-end | $1,074.68 | $772.00 | $582.92 | $365.84 | $276.22 | $168.84 | $131.43 | $115.72 | $84.46 | $73.55 |
| Per share | ||||||||||
| Revenue per share | $72.58 | $49.82 | $37.78 | $30.04 | $29.69 | $25.65 | $23.31 | $20.79 | $18.99 | $19.28 |
| Earnings per share | $22.98 | $11.71 | $5.80 | $6.57 | $5.85 | $6.47 | $8.69 | $3.13 | −$0.19 | $2.49 |
| Operating cash flow per share | $18.72 | $9.75 | $4.69 | $7.46 | $7.61 | $6.79 | $5.05 | $5.34 | $5.34 | $4.41 |
| Free cash flow per share | $9.99 | $4.16 | −$3.49 | $4.84 | $5.65 | $4.67 | $3.64 | $2.42 | $3.28 | $3.41 |
| Cash per share | $8.09 | $3.79 | $3.24 | $2.33 | $4.10 | $3.85 | $2.55 | $7.17 | $7.64 | $5.49 |
| Book value per share | $29.55 | $15.70 | $11.93 | $11.21 | $9.42 | $5.90 | $2.72 | $10.55 | $11.02 | $12.72 |
| Tangible book value per share | $15.72 | $2.49 | −$1.19 | −$0.66 | −$2.73 | −$5.83 | −$8.03 | $8.20 | $3.04 | $5.16 |
| Dividends per share | $6.00 | $5.18 | $4.51 | $3.72 | $3.24 | $2.81 | $2.52 | $2.24 | $2.08 | $1.96 |
| Capex per share | $8.73 | $5.59 | $8.18 | $2.61 | $1.96 | $2.12 | $1.41 | $2.92 | $2.06 | $0.99 |
| Debt per share | $47.33 | $37.21 | $27.93 | $17.09 | $17.71 | $17.35 | $16.50 | $12.33 | $12.97 | $9.36 |
| Shares outstanding | 898.0M | 904.1M | 903.3M | 950.2M | 953.7M | 956.6M | 957.5M | 1.03B | 1.05B | 1.10B |
| Change in shares outstanding | −0.7% | +0.1% | −4.9% | −0.4% | −0.3% | −0.1% | −7.4% | −1.7% | −4.4% | −0.4% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 101.4% | 84.8% | 48.9% | 63.6% | 76.4% | 150.2% | 123.1% | 28.7% | −1.6% | 19.2% |
| Return on invested capital (ROIC) | 44.9% | 36.7% | 29.9% | 34.1% | 35.5% | 35.8% | 32.8% | 30.8% | 12.0% | 17.3% |
| Return on assets (ROA) | 21.6% | 14.8% | 9.2% | 12.7% | 11.7% | 14.4% | 20.0% | 7.3% | −0.5% | 7.4% |
| Return on tangible assets | 20.6% | 15.9% | 10.0% | 16.3% | 15.0% | 17.5% | 28.7% | 7.8% | −0.6% | 9.0% |
| Free cash flow margin | 13.8% | 8.3% | −9.2% | 16.1% | 19.0% | 18.2% | 15.6% | 11.7% | 17.3% | 17.7% |
| Income quality (OCF / net income) | 0.81 | 0.83 | 0.81 | 1.13 | 1.30 | 1.05 | 0.58 | 1.71 | — | 1.77 |
| Financial health | ||||||||||
| Total debt | $42.50B | $33.64B | $25.23B | $16.24B | $16.88B | $16.60B | $15.80B | $12.74B | $13.65B | $10.31B |
| Cash & short-term investments | $7.27B | $3.42B | $2.93B | $2.21B | $3.91B | $3.68B | $2.44B | $7.41B | $8.03B | $6.04B |
| Net debt | $35.23B | $30.22B | $22.30B | $14.03B | $12.98B | $12.91B | $13.37B | $5.33B | $5.61B | $4.27B |
| Debt / equity | 1.60 | 2.37 | 2.34 | 1.52 | 1.88 | 2.94 | 6.06 | 1.17 | 1.18 | 0.74 |
| Debt / assets | 0.38 | 0.43 | 0.39 | 0.33 | 0.35 | 0.36 | 0.40 | 0.29 | 0.30 | 0.27 |
| Net debt / EBITDA | 1.11 | 1.61 | 2.60 | 1.62 | 1.61 | 1.45 | 1.94 | 0.96 | 1.37 | 0.84 |
| Current ratio | 1.58 | 1.15 | 0.94 | 1.05 | 1.23 | 1.40 | 1.16 | 1.73 | 1.32 | 1.37 |
| Quick ratio | 1.19 | 0.89 | 0.73 | 0.80 | 0.97 | 1.08 | 0.89 | 1.47 | 1.01 | 1.05 |
| Interest coverage | 37.3 | 21.8 | 22.2 | 26.1 | 23.3 | 20.1 | 15.0 | 24.8 | 18.9 | 20.9 |
| Working capital | $20.40B | $4.36B | −$1.57B | $896.3M | $3.40B | $4.98B | $1.93B | $8.66B | $4.67B | $4.11B |
| Invested capital | $61.77B | $44.41B | $33.07B | $24.68B | $21.96B | $18.56B | $15.97B | $16.24B | $17.21B | $18.27B |
| Tangible asset value | $14.12B | $2.33B | −$982.6M | −$504.2M | −$2.43B | −$5.39B | −$7.60B | $8.47B | $3.27B | $5.75B |
| Net current asset value | −$30.31B | −$31.70B | −$27.42B | −$20.68B | −$21.20B | −$23.35B | −$22.88B | −$12.45B | −$14.11B | −$9.62B |
| Graham number | $123.62 | $64.32 | $39.45 | $40.71 | $35.21 | $29.31 | $23.07 | $27.25 | — | $26.68 |
| Graham net-net per share | −$63.12 | −$52.29 | −$42.98 | −$29.39 | −$29.05 | −$31.30 | −$29.66 | −$19.07 | −$18.16 | −$12.11 |
| Capital allocation | ||||||||||
| Dividends paid | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B | $2.69B | $2.41B | $2.31B | $2.19B | $2.16B |
| Share buybacks (net) | $4.11B | $2.50B | $750.0M | $1.50B | $1.25B | $500.0M | $4.40B | $4.15B | $299.8M | $600.1M |
| Dividend payout ratio | 26.1% | 44.2% | 77.7% | 56.6% | 55.3% | 43.4% | 29.0% | 71.5% | — | 78.8% |
| Dividends + buybacks / free cash flow | 105.8% | 191.0% | — | 109.5% | 80.5% | 71.3% | 195.5% | 257.9% | 72.2% | 73.4% |
| Capex / revenue | 12.0% | 11.2% | 21.7% | 8.7% | 6.6% | 8.3% | 6.1% | 14.0% | 10.8% | 5.1% |
| Capex / operating cash flow | 46.6% | 57.4% | 174.3% | 35.1% | 25.8% | 31.2% | 28.0% | 54.6% | 38.5% | 22.5% |
| Capex / depreciation | 3.93 | 2.86 | 4.84 | 1.63 | 1.21 | 1.53 | 1.10 | 1.88 | 1.38 | 0.73 |
| Stock-based compensation / revenue | 1.0% | 1.4% | 1.8% | 1.3% | 1.2% | 1.3% | 1.4% | 1.3% | 1.4% | 1.2% |
| R&D / revenue | 20.5% | 24.4% | 27.3% | 25.2% | 24.5% | 24.4% | 25.1% | 23.5% | 25.5% | 25.0% |
| SG&A / revenue | 17.0% | 19.1% | 20.3% | 21.3% | 21.7% | 23.9% | 26.9% | 26.7% | 30.9% | 29.8% |
| Efficiency | ||||||||||
| Days sales outstanding | 93.6 | 99.7 | 106.4 | 106.7 | 97.0 | 92.7 | 92.5 | 93.7 | 91.6 | 76.0 |
| Days of inventory on hand | 352.3 | 289.7 | 259.8 | 225.6 | 196.3 | 238.7 | 243.1 | 294.6 | 329.1 | 224.0 |
| Days payables outstanding | 142.1 | 126.3 | 116.7 | 99.1 | 81.8 | 100.2 | 101.0 | 102.0 | 113.2 | 85.9 |
| Cash conversion cycle (days) | 303.7 | 263.1 | 249.5 | 233.2 | 211.6 | 231.2 | 234.7 | 286.2 | 307.5 | 214.1 |
| Receivables turnover | 3.90 | 3.66 | 3.43 | 3.42 | 3.76 | 3.94 | 3.94 | 3.89 | 3.98 | 4.80 |
| Payables turnover | 2.57 | 2.89 | 3.13 | 3.68 | 4.46 | 3.64 | 3.61 | 3.58 | 3.22 | 4.25 |
| Inventory turnover | 1.04 | 1.26 | 1.40 | 1.62 | 1.86 | 1.53 | 1.50 | 1.24 | 1.11 | 1.63 |
| Asset turnover | 0.68 | 0.63 | 0.60 | 0.58 | 0.59 | 0.57 | 0.54 | 0.48 | 0.48 | 0.57 |
| Average receivables | $16.72B | $12.31B | $9.95B | $8.34B | $7.53B | $6.24B | $5.66B | $5.52B | $5.01B | $4.42B |
| Average payables | $4.30B | $2.91B | $2.26B | $1.80B | $1.64B | $1.51B | $1.31B | $1.31B | $1.38B | $1.34B |
| Average inventory | $10.67B | $6.68B | $5.04B | $4.10B | $3.93B | $3.59B | $3.14B | $3.78B | $4.01B | $3.50B |
| Intangibles / total assets | 11.0% | 15.2% | 18.5% | 22.8% | 23.7% | 24.1% | 26.2% | 5.5% | 18.7% | 21.5% |
Computed from LLY's annual financial statements (latest annual report filed February 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LLY valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Eli Lilly traded at 46.8 times earnings, against a 10-year median of 46.8. Based on the latest twelve months, the trailing P/E is 42.2 and the forward P/E is 24.4. Eli Lilly earned a return on equity of 101.4% and a return on invested capital of 44.9% in fiscal 2025. It ended the year with $42.5 billion of debt and $7.3 billion in cash and short-term investments, net debt of $35.2 billion. It returned $9.5 billion to shareholders: $5.4 billion in dividends and $4.1 billion in share buybacks, 106% of free cash flow. The share count fell 18.4% from 1.10B to 898.0M over 9 years.
See the LLY income statement, the LLY chart for price history, or the LLY stock overview for the latest quote and news.
LLY key metrics FAQ
What is Eli Lilly's P/E ratio?
Eli Lilly's trailing P/E ratio is 42.2 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 24.4. At the end of fiscal 2025 it was 46.8, compared with a 10-year median of 46.8.
What is Eli Lilly's EV/EBITDA?
Eli Lilly's enterprise value was 31.6 times EBITDA at the end of fiscal 2025 (enterprise value $1.00 trillion, EBITDA $31.7 billion); the current EV/EBITDA is 25.7.
What is Eli Lilly's return on equity?
Eli Lilly's return on equity (ROE) was 101.4% in fiscal 2025: net income of $20.6 billion on average shareholders' equity of $20.4 billion. ROE is high partly because years of buybacks have reduced equity on the balance sheet.
What is Eli Lilly's ROIC?
Eli Lilly's return on invested capital was 44.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Eli Lilly have?
Eli Lilly had total debt of $42.5 billion at the end of fiscal 2025, a debt-to-equity ratio of 1.60 and $35.2 billion of net debt (1.11 times EBITDA).
What is Eli Lilly's dividend yield?
Eli Lilly's forward dividend yield is 0.55%. Eli Lilly paid $5.4 billion in dividends in fiscal 2025 ($6.00 per share), a payout ratio of 26.1%.
Does Eli Lilly buy back its shares?
Yes. Eli Lilly spent $4.1 billion on net share repurchases in fiscal 2025 Shares outstanding changed −0.7% over the year, to 898.0M..
What is Eli Lilly's free cash flow yield?
Eli Lilly generated $9.0 billion of free cash flow in fiscal 2025, a free cash flow yield of 0.9% on its market value at year-end ($965.1 billion).
What is Eli Lilly's current ratio?
Eli Lilly's current ratio was 1.58 at the end of fiscal 2025: current assets were 1.58 times current liabilities.